Physician profile
Arlo Miller
NPI 1407990161
$1,590.61
in general payments reported to CMS, 2019-2025
14 companies · $366 in 2025
The $366 reported for 2025 was less than what a typical Dermatology provider received nationally (typical 2025 total: $772).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $106 · 2021: $43.57 · 2022: $112 · 2023: $429 · 2024: $534 · 2025: $366.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,246 · Education: $82.95.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,246.24 |
| Education | $82.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $575.07 | 2022-2025 | |
| Sun Pharmaceutical Industries INC. | $226.63 | 2023-2025 | Absorica Ld |
| Genzyme Corporation | $178.51 | 2022-2025 | |
| Incyte Corporation | $175.02 | 2023-2025 | Opzelura, Opzelura |
| Allergan, INC. | $103.16 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $91.82 | 2019-2025 | |
| E.R. Squibb & Sons, L.L.C. | $51.56 | 2024 | Sotyktu |
| Merz North America, INC. | $49.28 | 2023 | Xeomin |
| Arcutis Biotherapeutics, INC. | $37.58 | 2024-2025 | Zoryve |
| Lilly USA, LLC | $24.49 | 2025 | Ebglyss, Taltz, Zepbound |
| Ucb, INC. | $24.27 | 2025 | Bimzelx |
| Janssen Biotech, INC. | $23.02 | 2021 | |
| Regeneron Healthcare Solutions, INC. | $16.73 | 2025 | Libtayo |
| Galderma Laboratories, L.P. | $13.47 | 2025 | Aklief |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Arlo Miller listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.